From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Mon, 24 Feb 2020 17:21:34 +0000

To: Van Hoof, Johan [JRDBE];Erbelding, Emily (NIH/NIAID) [E]
Ce: Stoffels, Paul [JICUS]

Subject: RE: as26 based COVID-19 vaccine candidate

Johan:

Thanks for the note. | enjoyed and learned from your presentation this
morning. The best way to keep in touch with NIAID would be through Emily and
Barney.

Best regards,.
Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (Ww

FAX: (301) 496-4409

E-mail:— HY 5)

The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

From: Van Hoof, Johan [JRDBEJf OF

Sent: Monday, February 24, 2020 11:58 AM

To: Erbelding, Emily (NIH/NIAID) [E] ff) >
Ce: Fauci, Anthony (NIH/NIAID) [E)[ —___. ©») ©} Stoffels, Paul (JICUS] Ho OF

Subject: as26 based COVID-19 vaccine candidate

 

Dear Emily,
Dear Dr. Fauci,

First of all, ! want to thank NIAID and its team for spending time with us going through the Janssen plans
for Ad 26 COVID-19 vaccine development.

In follow up of our call earlier today, please find herewith the key action points | noted from our
discussion. | would welcome your perspectives/comments, as well as the best way to keep in touch with
NIAID.

Looking forward to your feedback,

NIH-001443
